GlassScriptPhysician profile
Vishak Johny John
NPI 1255515623
$155,695.72
in general payments reported to CMS, 2019-2025
26 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $8,507 · 2021: $4,784 · 2022: $34K · 2023: $27K · 2024: $40K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Consulting Fee: $22K · Honoraria: $13K · Food and Beverage: $4,694 · Travel and Lodging: $1,856 · Education: $17.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,178.50 |
| Consulting Fee | $21,687.00 |
| Honoraria | $13,277.50 |
| Food and Beverage | $4,693.89 |
| Travel and Lodging | $1,856.17 |
| Education | $17.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $97,915.71 | 2019-2025 | Vabysmo, Susvimo, Lucentis |
| Alimera Sciences, INC. | $29,984.58 | 2019-2024 | Iluvien, Yutiq |
| Allergan, INC. | $6,315.69 | 2019-2021 | |
| F. Hoffmann-La Roche Ag | $5,129.63 | 2023-2024 | Vabysmo |
| Genentech, INC. | $3,155.16 | 2020-2024 | Vabysmo, Susvimo |
| Astellas Pharma US INC | $2,700.35 | 2023-2025 | Izervay |
| Glaukos Corporation | $2,678.50 | 2023-2024 | Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3, Kxl System (Not Refurbished) |
| Regeneron Healthcare Solutions, INC. | $2,477.26 | 2019-2025 | Eylea Hd, Eylea |
| Ani Pharmaceuticals, INC. | $2,438.66 | 2024-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Abbvie INC. | $752.44 | 2022-2025 | |
| Notal Vision, INC. | $615.80 | 2019-2025 | Foresee Home |
| Bausch & Lomb Americas INC. | $306.23 | 2022-2025 | Xipere, Stellaris, Visudyne |
| Eyepoint US, INC. | $246.43 | 2019-2023 | |
| Regeneron Pharmaceuticals, INC. | $209.91 | 2025 | Eylea Hd |
| Biogen, INC. | $175.56 | 2022-2024 | Byooviz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $175.29 | 2023-2025 | Syfovre |
| Coherus Oncology, INC. | $95.58 | 2022-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $89.22 | 2019-2021 | |
| Harrow Eye, LLC | $75.96 | 2024-2025 | Iheezo, Triesence |
| Novartis Pharmaceuticals Corporation | $38.20 | 2019-2020 | |
| Carl Zeiss Meditec, INC. | $37.77 | 2019 | |
| Ocular Therapeutix, INC. | $26.92 | 2024 | Dextenza |
| Carl Zeiss Meditec USA, INC. | $21.75 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Neurotech Pharmaceuticals, INC. | $13.72 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishak John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.